Response to interferon-γ plus pentavalent antimony in Indian visceral leishmaniasis

Journal of Infectious Diseases

Volumn 176, Issue 4, 1997, Pages 1117-1119

  Sundar, Shyam ^a   Singh, Vijay P ^a   Sharma, Shasi ^a   Makharia, Manoj K ^a   Murray, Henry W ^a  

^a Box 130 ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY GLUCONATE; PARACETAMOL; RECOMBINANT GAMMA INTERFERON;

ADULT; AMASTIGOTE; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GIEMSA STAIN; HEART ARRHYTHMIA; HUMAN; INDIA; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SPLEEN; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

EID: 0030765367     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/516526     Document Type: Article

References (15)

1. Sundar S, Rosenkaimer F, Lesser M, Murray HW. Immunochemotherapy for an intracellular infection: accelerated response using interferon-γ in visceral leishmaniasis. J Infect Dis 1995;171:992-6.
2. Thakur CP, Kumar M, Pandey AK. Comparison of regimens of treatment of antimony-resistant kala-azar patients. Am J Trop Med Hyg 1991;45: 435-41.
3. Mishra M, Biswas UK, Jha DN, Khan AB. Amphotericin B versus pentamidine in antimony-unresponsive kala-azar. Lancet 1992;340:1256-7.
4. Olliaro PL, Bryceson ADM. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today 1993;9:323-8.
5. Thakur CP, Kumar M, Kumar P, Mishra BN, Pandey AK. Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomized study. Br Med J Clin Res Ed 1988;296:1557-61.
6. Murray HW, Rubin BY, Rothermel CD. Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-γ is the activating lymphokine. J Clin Invest 1983;72:1506-10.
7. Murray HW. Interferon-γ in host antimicrobial defense: current and future clinical applications. Am J Med 1994;97:459-67.
8. Badaro R. The role of interferon-γ in the treatment of visceral and diffuse cutaneous leishmaniasis. J Infect Dis 1993;167(suppl 1):S13-7.
9. Sundar S, Rosenkaimer F, Murray HW. Successful treatment of refractory visceral leishmaniasis in India using antimony plus IFN-γ. J Infect Dis 1994;170:659-63.
10. Sundar S, Murray HW. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex. J Infect Dis 1996; 173:762-5.
11. Squires K, Rosenkaimer F, Sherwood JA, Were JBO, Murray HW. Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony vs. antimony plus interferon-γ. Am J Trop Med Hyg 1993; 48:666-9.
12. Singh NKP, Sharma D, Jha TK. Kala-azar mortality in hospitalized cases in north Bihar, India. J Assoc Physicians India 1989;37:514-6.
13. Jha TK, Giri YN, Singh TK, Jha S. Use of amphotericin B in drug-resistant cases of visceral leishmaniasis in north Bihar, India. Am J Trop Med Hyg 1995;52:536-8.
14. Sundar S, Agrawal NK, Sinha PK, Horwith GS, Murray HW. Short-course, low-dose amphotericin B lipid complex therapy for antimony-unresponsive visceral leishmaniasis. Ann Intern Med 1997;127:133-7.
15. Thakur CP, Olliaro P, Gothoskar S, et al. Treatment of visceral leishmaniasis (kala-azar) with aminosidine-antimonial combinations, a pilot study in Bihar, India. Trans Roy Soc Trop Med Hyg 1992;86:615-6.